Article
Multidisciplinary Sciences
Laure Bidou, Olivier Bugaud, Goulven Merer, Matthieu Coupet, Isabelle Hatin, Egor Chirkin, Sabrina Karri, Stephane Demais, Pauline Francois, Jean-Christophe Cintrat, Olivier Namy
Summary: In this study, a new drug was developed and evaluated for its clinical potential in treating genetic diseases caused by premature termination codons (PTCs). The drug, TLN468, was found to be more effective than the currently used gentamicin and acted on a broader range of sequences without affecting normal stop codon readthrough.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Biochemistry & Molecular Biology
Patricia Martins-Dias, Luisa Romao
Summary: Nonsense mutations can lead to dysfunctional proteins, but nonsense suppression therapy has the potential to restore protein function and treat a variety of genetic disorders. However, the efficiency of suppression may be influenced by nonsense-mediated decay, highlighting the importance of using NMD inhibitors or readthrough-compound potentiators to enhance therapeutic effects.
CELLULAR AND MOLECULAR LIFE SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Venkateshwar Mutyam, Jyoti Sharma, Yao Li, Ning Peng, Jianguo Chen, Li Ping Tang, Emily Falk Libby, Ashvani K. Singh, Katja Conrath, Steven M. Rowe
Summary: Premature-termination codons (PTCs) in the CFTR gene lead to nonfunctional CFTR protein, accounting for 11% of CF-causing alleles with no current effective treatments. Novel CFTR correctors and potentiators show comparable effects to existing ones in vitro, and their combination can enhance the improvement of CFTR function with terminal PTC mutations.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
(2021)
Article
Biology
Martine Palma, Fabrice Lejeune
Summary: Recognition of the stop codon is crucial for terminating translation and synthesizing the correct size protein. Stop codon readthrough can occur under specific conditions, leading to different protein isoforms, and has potential therapeutic implications for genetic diseases caused by nonsense mutations.
BIOLOGICAL REVIEWS
(2021)
Article
Pharmacology & Pharmacy
Renata B. V. Abreu, Thiago T. Gomes, Thales C. Nepomuceno, Xueli Li, Mateus Fuchshuber-Moraes, Giuliana De Gregoriis, Guilherme Suarez-Kurtz, Alvaro N. A. Monteiro, Marcelo A. Carvalho
Summary: This study evaluates the readthrough of clinically relevant PTC variants in the breast and ovarian cancer-predisposing gene BRCA1 for the first time, demonstrating that the aminoglycoside G418 can induce PTC readthrough and restore full-length protein synthesis and function.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Chemistry, Medicinal
Michael Popadynec, Alireza Baradaran-Heravi, Benjamin Alford, Scott A. Cameron, Keith Clinch, Jennifer M. Mason, Phillip M. Rendle, Olga Zubkova, Zhonghong Gan, Hui Liu, Oscar Rebollo, Dennis M. Whitfield, Fengyang Yan, Michel Roberge, David A. Powell
Summary: Aminoglycosides have the potential to induce readthrough of premature termination codons, which could be valuable in treating genetic diseases. Modification of aminoglycoside compounds to reduce cellular toxicity while maintaining readthrough activity is a strategy documented in this study.
ACS MEDICINAL CHEMISTRY LETTERS
(2021)
Article
Biochemistry & Molecular Biology
Soushi Kobayashi, Akira Kaji, Hideko Kaji
Summary: Eukaryotic elongation factor 3 (eEF3) stimulates the release of mRNA from puromycin-treated polysomes. When eEF3 is partially removed from the crude extract, a UAA stop codon readthrough occurs, leading to an increase in the downstream ORF product. eEF3 enhances the release of luciferase from polysomes by eukaryotic release factor (eRF)1 and eRF3. These findings suggest that eEF3 assists eRFs in performing normal protein synthesis termination in yeast.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2023)
Article
Cell Biology
Lekha E. Manjunath, Anumeha Singh, Saubhik Som, Sandeep M. Eswarappa
Summary: This review discusses how recent technological and computational advances have increased our understanding of the stop codon readthrough process in the mammalian system. We propose transient molecular roadblocks as a possible mechanism for the induction of stop codon readthrough and argue that insights from natural readthrough events can guide the development of novel disease treatment strategies.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2023)
Article
Biochemistry & Molecular Biology
Daniel R. McHugh, Calvin U. Cotton, Craig A. Hodges
Summary: This study demonstrated synergy between NMD inhibitors and readthrough agents in increasing functional protein quantity following readthrough, suggesting a potential therapeutic option for treating nonsense mutations.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Debaleena Kar, Debraj Manna, Lekha E. Manjunath, Anumeha Singh, Saubhik Som, Kirtana Vasu, Sandeep M. Eswarappa
Summary: This study used a mathematical model to analyze the process of stop codon readthrough (SCR) and found that the translation rate inversely regulates the efficiency of SCR. Experimental results confirmed that reducing translation can increase the efficiency of SCR. This study has revealed a previously unknown mode of regulation for SCR.
JOURNAL OF MOLECULAR BIOLOGY
(2023)
Review
Cell Biology
Joseph J. Porter, Christina S. Heil, John D. Lueck
Summary: Nonsense mutations create defective truncated proteins by changing amino acid codons. While most PTC therapeutics focus on promoting PTC read-through, there is a need for agents that can recode PTCs with the correct amino acids.
WILEY INTERDISCIPLINARY REVIEWS-RNA
(2021)
Article
Biochemistry & Molecular Biology
Lukana Ngiwsara, Phannee Sawangareetrakul, Duangrurdee Wattanasirichaigoon, Thipwimol Tim-Aroon, Prapai Dejkhamron, Voraratt Champattanachai, James R. Ketudat-Cairns, Jisnuson Svasti
Summary: This study investigated the effect of gentamicin on stop codon readthrough of IDUA variants and found that gentamicin significantly increased the expression and activity of IDUA. Changes in RNA secondary structure were observed in variants that responded to readthrough. Further studies in patient's skin fibroblasts and animal models are needed for personalized medicine.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2022)
Article
Chemistry, Medicinal
Christie Morrill, Westley J. Friesen, Suresh Babu, Ramil Y. Baiazitov, Wu Du, Diane B. Karloff, Chang -Sun Lee, Young-Choon Moon, Hongyu Ren, Jairo Sierra, Yuki Tomizawa, Priya Vazirani, Ellen M. Welch, Xiaojiao Xue, Jin Zhuo
Summary: Using small molecules to induce readthrough is an effective method for treating genetic diseases and cancers. This study introduces a series of novel compounds that show potential for inducing readthrough in cells, either as combination therapy or standalone treatment.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
(2022)
Article
Biochemistry & Molecular Biology
Mikel D. D. Ghelfi, Saleem Y. Y. Bhat, Hong Li, Barry S. S. Cooperman
Summary: The research findings show that Ataluren acts as a competitive inhibitor, blocking the catalytic function of the release factor complex (RFC) and inducing readthrough. This opens up the possibility of discovering new readthrough-inducing drugs that are both low in toxicity and more effective at stimulating readthrough.
Article
Multidisciplinary Sciences
Jyoti Sharma, Ming Du, Eric Wong, Venkateshwar Mutyam, Yao Li, Jianguo Chen, Jamie Wangen, Kari Thrasher, Lianwu Fu, Ning Peng, Liping Tang, Kaimao Liu, Bini Mathew, Robert J. Bostwick, Corinne E. Augelli-Szafran, Hermann Bihler, Feng Liang, Jerome Mahiou, Josef Saltz, Andras Rab, Jeong Hong, Eric J. Sorscher, Eric M. Mendenhall, Candice J. Coppola, Kim M. Keeling, Rachel Green, Martin Mense, Mark J. Suto, Steven M. Rowe, David M. Bedwell
Summary: In this study, compounds with readthrough activity were identified and shown to reduce premature termination associated with cystic fibrosis by lowering eRF1 levels. These compounds, including SRI-41315 and SRI-37240, have potential as promising treatment strategies for diseases caused by PTCs.
NATURE COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Kohei Omachi, Shota Kaseda, Tsubasa Yokota, Misato Kamura, Keisuke Teramoto, Jun Kuwazuru, Haruka Kojima, Hirofumi Nohara, Kosuke Koyama, Sumio Ohtsuki, Shogo Misumi, Toru Takeo, Naomi Nakagata, Jian-Dong Li, Tsuyoshi Shuto, Mary Ann Suico, Jeffrey H. Miner, Hirofumi Kai
Summary: Metformin is commonly used for treating type 2 diabetes, and recent studies have suggested its potential in ameliorating tumor progression, inflammatory diseases, and fibrosis. This study found that metformin not only improved non-diabetic glomerular diseases and chronic kidney disease phenotypes, but also influenced metabolic and inflammatory pathways in the transcriptome analysis.
SCIENTIFIC REPORTS
(2021)
Article
Biotechnology & Applied Microbiology
Minori Tamai, Shinichi Fujisawa, Thao T. T. Nguyen, Chiaki Komatsu, Keiko Kagami, Kenji Kamimoto, Kohei Omachi, Shin Kasai, Daisuke Harama, Atsushi Watanabe, Koshi Akahane, Kumiko Goi, Kazuhito Naka, Tadashi Kaname, Takanori Teshima, Takeshi Inukai
Summary: The Philadelphia chromosome, generated by aberrant ligation between the BCR and ABL1 genes, is the first translocation identified in leukemia. Simultaneous double-strand breaks at the breakpoints of these genes have been found to be the initiation events for Ph+ leukemia and lead to the fusion of BCR and ABL1.
CANCER GENE THERAPY
(2023)
Article
Multidisciplinary Sciences
Shumeng Jiang, Farid Alisafaei, Yin-Yuan Huang, Yuan Hong, Xiangjun Peng, Chengqing Qu, Pongpratch Puapatanakul, Sanjay Jain, Jeffrey H. Miner, Guy M. Genin, Hani Y. Suleiman
Summary: Chronic kidney diseases are widespread and incurable, and the underlying biophysical mechanisms are unclear. Sarcomere-like structures (SLSs) have been identified in injured kidney podocytes, and they may play a role in the regeneration process. Results from an ex vivo culture system supported this hypothesis, suggesting SLSs as potential mechanobiological mediators for podocyte recovery.
Article
Multidisciplinary Sciences
Yasuhiro Yoshimura, Yoshiharu Muto, Nicolas Ledru, Haojia Wu, Kohei Omachi, Jeffrey H. Miner, Benjamin D. Humphreys
Summary: Comparing the gene regulatory landscape between kidney organoids and adult human kidney can help evaluate the differentiation progress at the epigenome and transcriptome level. The study found that organoid cell types have more open chromatin compared to adult human kidney. Using enhancer dynamics analysis, the researchers validated an enhancer that drives transcription of HNF1B during organoid differentiation. This study provides an experimental framework to assess the cell-specific maturation state of human kidney organoids and validates gene regulatory networks involved in differentiation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2023)
Article
Urology & Nephrology
Yasuhiro Yoshimura, Yoshiharu Muto, Kohei Omachi, Jeffrey H. Miner, Benjamin D. Humphreys
Summary: This study reveals the regulatory mechanisms of HNF4A and HNF4G during human proximal tubule differentiation. The experimental strategy can be applied more broadly to investigate transcriptional regulation in human kidney development.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Article
Urology & Nephrology
Jun Kuwazuru, Mary Ann Suico, Kohei Omachi, Haruka Kojima, Misato Kamura, Shota Kaseda, Teppei Kawahara, Yuki Hitora, Hikaru Kato, Sachiko Tsukamoto, Mikiyo Wada, Toshifumi Asano, Shunsuke Kotani, Makoto Nakajima, Shogo Misumi, Yuya Sannomiya, Jun Horizono, Yuimi Koyama, Aimi Owaki, Tsuyoshi Shuto, Hirofumi Kai
Summary: This study provides a novel therapeutic candidate, alisporivir, for Alport syndrome (AS) by enhancing the secretion of mutant 345(IV) and reveals the importance of cyclophilin D in this process. It suggests that alisporivir could be a safer option than cyclosporin A for AS treatment.
Article
Urology & Nephrology
Kohei Omachi, Colin O'Carroll, Jeffrey H. Miner
Summary: This study investigated the effects of PPARd agonist REN001 in a mouse model of Alport syndrome. The results showed that REN001 reduced proteinuria, decreased BUN levels, and improved renal inflammation and fibrosis. The combination of REN001 with ACEis may have additive effects to attenuate renal injury and slow disease progression.
Article
Urology & Nephrology
Jennefer Kohler, Kohei Omachi, Vivek Charu, Jeffrey H. Miner, Vivek Bhalla
Summary: The study utilized cell-based assays to confirm the disruptive effect of the COL4A4-G394S variant on the assembly of collagen IV heterotrimers, leading to an atypical mild form of autosomal recessive Alport syndrome.
Article
Physiology
Liang Ning, Hani Y. Suleiman, Jeffrey H. Miner
Summary: In a study investigating the impact of Synaptopodin (Synpo) deficiency on Alport syndrome (AS) in mice, it was found that lack of Synpo accelerated disease progression, leading to more severe proteinuria and glomerulosclerosis. The absence of Synpo also affected the distribution of myosin IIA in podocytes, suggesting that the actin cytoskeleton of podocytes could be a potential therapeutic target in AS.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY
(2021)